SJS Investment Consulting’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,144
Closed -$1.92K – 3319
2026
Q2
$1.92K Buy
1,144
+1,094
+2,188% +$1.59K ﹤0.01% 1793
2026
Q1
$66 Buy
+50
New +$89 ﹤0.01% 2216
2024
Q2
– Sell
-6
Closed -$23 – 1697
2024
Q1
$23 Sell
6
-3
-33% -$18 ﹤0.01% 1634
2023
Q4
$89 Buy
9
+3
+50% +$25 ﹤0.01% 1561
2023
Q3
$51 Sell
6
-3
-33% -$34 ﹤0.01% 1587
2023
Q2
$120 Buy
9
+3
+50% +$36 ﹤0.01% 1488
2023
Q1
$70 Buy
+6
New +$60 ﹤0.01% 1489

Other funds holding PACB

SJS Investment Consulting's PACB Position: Q3 2026 in Review

SJS Investment Consulting sold out of Pacific Biosciences (PACB) in Q3 2026, closing a stake of 1,144 shares — an estimated $1.92K sold.

SJS Investment Consulting first reported a position in PACB in Q1 2023 and held it in 7 quarters. The position peaked at $1.92K in Q2 2026. 205 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • SJS Investment Consulting reported no remaining Pacific Biosciences position as of Q3 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 1,144 Pacific Biosciences shares in Q3 2026, an estimated $1.92K.
  • SJS Investment Consulting first reported a position in Pacific Biosciences in Q1 2023 and held it in 7 quarters.
  • SJS Investment Consulting's Pacific Biosciences position peaked at $1.92K in Q2 2026.
  • 205 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.